Drug intelligence / Profile preview

GK21

Development stage: Preclinical
Lead developer: Zhiyi Pharmaceutics
Modality: Live Biotherapeutic Products → Microbiome Therapeutics

Overview

GK21 is a preclinical live biotherapeutic product (LBP) being developed by Zhiyi Biotechnology. It is classified as a Class 1 Biological Product. The specific mechanism of action and the intended therapeutic indications for GK21 have not been disclosed by the company.

Beyond the preview

Go deeper on GK21.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GK21.

Explore the full profile